Posted by Michael Wonder on 15 Dec 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population.
Valeo Pharma is proud to announce a major milestone for its two innovative asthma therapies ; Atectura Breezhaler and Enerzair Breezehaler are now reimbursed by the Quebec RAMQ, and by Nova Scotia Minister of Health, effective 15 December 2021 and 2 December 2021 respectively.
The listings now appear on the Quebec List of Medications and the Nova Scotia Drug Formulary.
